Freshfields Bruckhaus Deringer has advised China Feihe Limited on the US$856m global offering and listing of its shares on the Hong Kong Stock Exchange.
Trading in the shares commenced today (13 November 2019).
China Feihe is China’s largest and most well-known maker of infant milk formula. With many years of experience in the infant milk formula space, China Feihe has developed a unique value proposition as the ‘most suitable brand for Chinese babies’. Its products are designed to closely replicate the composition of the breast milk of Chinese mothers through in-house research and development formulations, with the aim of achieving an optimal balance of key ingredients for Chinese babies. China Feihe has formed collaborative partnerships with leading national and international research institutions to support its research into nutrition for infants and adults. Moreover, China Feihe consistently sources the highest quality fresh milk for use in the production of all of its infant milk formula products. Among other purposes, China Feihe intends to use the proceeds of its IPO to repay loans, to fund potential M&A and R&D activities and to maintain and expand its operations.
The Freshfields team advising on the transaction was led by partner and Head of China ECM Richard Wang (Picture) and partner Calvin Lai.
Law Firms: Freshfields Bruckhaus Deringer LLP;
Clients: China Feihe Limited ;